Abouch Valenty Krymchantowski
Headache Center of Rio, Rio de Janeiro, Brazil. | Headache Center of Rio, Rio de Janeiro, Brazil | Department of Neurology, Headache Center of Rio, Rio de Janeiro, Brazil | ...
KOL Resume for Abouch Valenty Krymchantowski
Headache Center of Rio, Rio de Janeiro, Brazil.
Headache Center of Rio, Rio de Janeiro, Brazil
Department of Neurology, Headache Center of Rio, Rio de Janeiro, Brazil
Centro de Avaliação e Tratamento da Dor de Cabeça, Rio de Janeiro, Brasil
Centro de Avaliação e Tratamento da Dor de Cabeça do Rio de Janeiro, Rio de Janeiro, RJ, Brasil, Centro de Avaliação e Tratamento da Dor de Cabeça do Rio de Janeiro, Rio de Janeiro RJ, Brasil
Headache Center of Rio, Rio de Janeiro, further author information
Headache Center of Rio, Rio de Janeiro 22031-071, Brazil;,
The Headache Center of Rio Rio de Janeiro Brazil
Headache Headache Center of Rio Rio de Janeiro Brazil
Universidade Federal de Minas Gerais Headache Clinic Belo Horizonte Minas Gerais Brazil
From the Headache Clinic, UFMG, Belo Horizonte, Brazil (A.A. Silva Junior, R.S. Gomez); Merck Research Laboratories, Whitehouse Station, NJ, USA (M. Bigal, A.L. Teixeira); Internal Medicine, UFMG, Belo Horizonte, Brazil (L.P.B. Vasconcelos); Medicine, UNIFENAS, Belo Horizonte, Brazil (J. Rodrigues); Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil (A.V. Krymchantowski); Headache Clinic, Fluminense Federal University, University Hospital, Rio de Janeiro, Brazil (P. Moreira Filho); Laboratory of Immunopharmacology, UFMG, Belo Horizonte, Brazil (A.L. Teixeira).
MD, PhD, Headache Center Of Rio de Janeiro, Brazil
Headache Center of Rio, Rua Siqueira Campos 43/1002, Copacabana, 22031-070, Rio de Janeiro, Brazil
FAHS Headache Center of Rio and Dept of Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil.
From the University Hospital, Federal University of Minas Gerais (UFMG) – Headache Clinic, Neurology Division, Belo Horizonte, Brazil (Ariovaldo S. Junior, Luiz Paulo Vasconcelos, Rodrigo S. Gomez, and Antonio Lucio Teixeira); UniversidadeFederal Fluminense, Niterói, Rio de Janeiro, Brazil (A. Krymchantowski, and P. Moreira). [Correction added after online publication 28‐Apr‐2009: Author affiliations update.]
Merck Research Laboratories, Whitehouse Station, U.S
Universidade Federal Fluminense – Neurology, Rio de Janeiro, Brazil
Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil
Headache Center of Rio de Janeiro, Rio de Janeiro, Brazil
Headache Center of Rio, Rua Siqueira Campos 43/1002 Copacabana, Rio de Janeiro, 22031.070, Brazil. www.dordecabeca.com.br
Rio de Janeiro, RJ, Cia Atlhética, Brazil
Instituto de Neurologia Deolindo Couto
Outpatient Headache Unit, Instituto de Neurologia Deolindo Couto, Department of Neurology, Hospital Pasteur, Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil.
Headache Center of Rio, University Federal Fluminense, Brazil.
Department of Neurology, Universidade Federal Fluminense, Niterói, Brazil
Rio de Janeiro, RJ, Instituto de Neurologia Deolindo Couto, Brasil
Universidade Federal Fluminense
Headache Center of Rio
Department of Neurology, Albert Einstein College of Medicine, 1125 Morris Park Avenue, office 334 A, Bronx, New York, USA
From the Headache Center of Rio and Instituto de Neurologia Deolindo Couto/UFRJ, Rio de Janeiro, Brazil
Headache Center of Rio and Institute of Neurology Deolindo Couto
UFRJ, Rio de Janeiro, Brasil
Universidade Federal do Rio de Janeiro
Universidade Federal do Rio de Janeiro (UFRJ)
Centra de Avaliação e Tratamento da dor de Cabeça do Rio de Janeiro, Headache Center of Rio de Janeiro, Rio de Janeiro, Brazil
Centro de Avaliação e Tratamento da Dor de Cabeça, Rio de Janeiro
Abouch Valenty Krymchantowski: Influence Statistics
|intravenous lysine clonixinate||#1|
|memantine preventive treatment||#1|
|patients comprehensive approaches||#1|
|study 30 minutes||#1|
|headaches external compression||#1|
|tth clinical practice||#1|
|welldefined headache disorders||#1|
|combination triptan nsaid||#1|
|ndh patients treatment||#1|
|attack 2 attacks||#1|
|weeks headache frequency||#1|
|qtp preventive treatment||#1|
|neardaily headache patients||#1|
|opioids 5 weeks||#1|
|5 attacks patients||#1|
|consumption rescue medications||#1|
|2 regions brazil||#1|
|rizatriptan efficacy rates||#1|
|headache clinics brazil||#1|
|migraine recurrence sumatriptan||#1|
Open the FULL List in Excel
Prominent publications by Abouch Valenty Krymchantowski
Rizatriptan Combined with Rofecoxib Vs. Rizatriptan for the Acute Treatment of Migraine: an Open Label Pilot Study
[ PUBLICATION ]
Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice. Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of ...
|Known for Acute Treatment | Rizatriptan Rofecoxib | Headache Recurrence | 1 2 | Migraine Nsaids|
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine
[ PUBLICATION ]
BACKGROUND: Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. Some nonsteroidal anti-inflammatory drugs (NSAID) have also demonstrated efficacy in treating migraine attacks. There is evidence that the combination of a triptan and a NSAID decreases migraine recurrence in clinical practice. The primary aim of this randomized open label study was to assess the recurrence rates in migraine sufferers acutely treated with rizatriptan (RI) alone vs. ...
|Known for Acute Treatment | Migraine Attacks | Study Combination | Recurrence Rates | Treated Rizatriptan|
Although sumatriptan is an effective drug for the treatment of acute migraine attacks, recurrence has been cited as an important limitation for its use. Tolfenamic acid is also effective in the acute treatment of migraine attacks. We studied the recurrence rate of migraine attacks with the use of sumatriptan plus tolfenamic acid among patients who presented frequent recurrence with sumatriptan. Fifty migraineurs were retrospectively studied, all having treated at least 10 attacks with ...
|Known for Tolfenamic Acid | Migraine Recurrence | Treated Attacks | Acute Treatment | Combination Female Humans|
Forty to 78% of the patients using sumatriptan for the acute treatment of migraine may present recurrence at least occasionally. The concomitant use of a NSAID (nonsteroidal anti-inflammatory drug) has been recommended to decrease the recurrence rate. Sixty seven patients that treated successfully 8 migraine attacks with 100 mg of sumatritpan PO and presented recurrence in at least 5 attacks were studied prospectively. The patients received 100 mg of sumatriptan and 550 mg of naproxen ...
|Known for Naproxen Sodium | Migraine Recurrence | Combination Sumatriptan | Acute Treatment | Attacks Patients|
Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug
[ PUBLICATION ]
BACKGROUND AND OBJECTIVES: Triptans are effective drugs for the acute treatment of migraine. However, 30-40% of the patients commonly present recurrence before 24 hours therefore requiring another dose. Nonsteroidal anti-inflammatory drugs (NSAID) such as tolfenamic acid and naproxen sodium combined with sumatriptan have demonstrated efficacy in reducing recurrence observed with the single use of this drug. Steroids also have been suggested to treat refractory migraine and status ...
|Known for Migraine Recurrence | Dexamethasone Patients | Anti Inflammatory | Acute Treatment | Agents Steroidal|
Chronic Headache and Comorbibities: A Two‐Phase, Population‐Based, Cross‐Sectional Study
[ PUBLICATION ]
BACKGROUND: Studies using resources of a public family health program to estimate the prevalence of chronic daily headaches (CDH) are lacking.
OBJECTIVES: To estimate the 1-year prevalence of CDH, as well as the presence of associated psychiatric and temporomandibular disorders (TMD) comorbidities, on the entire population of a city representative of the rural area of Brazil.
METHODS: This was a cross-sectional, population-based, 2-phase study. In the first phase, health agents ...
|Known for Chronic Headache | Psychiatric Comorbidities | Cdh Tmd | Temporomandibular Disorders | International Classification|
Rizatriptan Vs. Rizatriptan Plus Trimebutine for the Acute Treatment of Migraine: A Double-Blind, Randomized, Cross-Over, Placebo-Controlled Study
[ PUBLICATION ]
Gastroparesis frequently happens during migraine attacks, postponing the onset of action of orally administered drugs. Furthermore, triptans seem to work better in the earlier phases of the migraine attacks. Therefore, associating a gastrokinetic drug with a triptan may translate into better efficacy and higher consistency of response. Trimebutine is an opioid derivative with exclusive action on receptors of the Meissner and Auerbach plexus throughout the digestive tube. It has no ...
|Known for Acute Treatment | Migraine Attacks | Gastrokinetic Drug | Serotonin Receptor | Gastrointestinal Agents|
Wine and Headache
[ PUBLICATION ]
BACKGROUND: The notion of migraine attacks triggered by food and beverages has been posited for centuries. Red wine in particular has been acknowledged as a migraine trigger since antiquity when Celsus (25 B.C.-50 A.D.) described head pain after drinking wine. Since then, references to the relationship between alcohol ingestion and headache attacks are numerous. The most common initiator of these attacks among alcoholic beverages is clearly wine. The aim of this review is to present and ...
|Known for Headache Attacks | Wine Ingestion | Migraine Trigger | Alcoholic Beverages | Medline Search|
The Medical Management of Migraine
[ PUBLICATION ]
Migraine is a common, chronic neurologic disorder that affects 11% of the adult population in Western countries. In this article, we review the current approaches to the pharmacologic treatment of migraine. Once migraine is diagnosed, and illness severity has been assessed, clinicians and patients should work together to develop a treatment plan based on the patient needs and preferences. The goals of the treatment plan usually include reducing attack frequency, intensity, and duration; ...
|Known for Medical Management | Simple Analgesics | Treatment Plan | Clinicians Individual Patient | Acute Drugs|
Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study
[ PUBLICATION ]
Several oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective to treat migraine attacks. Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS ...
|Known for Acute Treatment | Lysine Clonixinate | Migraine Attacks | Patients Placebo | Controlled Study|
OBJECTIVE: To estimate the 1-year prevalence of headache, using face-to-face interviews of the entire population of a city in Brazil.
METHODS: This was a cross-sectional, population-based study. We conducted face-to-face interviews of all individuals older than 10 years, in a town (Capela Nova) in Brazil. Prevalence of the headache was estimated using prevalence ratios, adjusted by gender, age, marital status, and level education.
RESULTS: The estimated 1-year prevalence of any headache ...
|Known for Prevalence Headache | Entire Population | Small City | 10 Years | Educational Status|
The majority of the patients who seek medical care in tertiary headache centres present with transformed migraine, and convert to daily headache, as a result of excessive intake of symptomatic medications (SM). This study aimed to analyse the possibility of using a short course of oral prednisone for detoxifying patients with chronic daily headache due to medication overuse in an out-patient setting. Four hundred patients with headache occurring more than 28 days per month for longer ...
|Known for Daily Headache | Symptomatic Medications | Outpatient Setting | Medication Overuse | Transformed Migraine|
Amitriptyline Versus Amitriptyline Combined With Fluoxetine in the Preventative Treatment of Transformed Migraine: A Double‐Blind Study
[ PUBLICATION ]
BACKGROUND AND OBJECTIVES: Antidepressants are often used to treat chronic daily headache disorders such as transformed migraine, in part because of the high prevalence of associated mood disorder. We conducted this study to evaluate the efficacy and tolerability of combined treatment with amitriptyline and fluoxetine compared with amitriptyline alone for chronic daily headache due to transformed migraine.
PATIENTS AND METHODS: Thirty-nine patients, 26 women and 13 men, aged 20 to 69 ...
|Known for Transformed Migraine | Headache Disorders | Versus Amitriptyline | Therapy Combination | Chronic Daily|
TEV-48125 for the preventive treatment of chronic migraine
[ PUBLICATION ]
OBJECTIVE: To evaluate the onset of efficacy of TEV-48125, a monoclonal antibody against calcitonin gene-related peptide, recently shown to be effective for the preventive treatment of chronic migraine (CM) and high-frequency episodic migraine.
METHODS: A randomized placebo-controlled study tested once-monthly injections of TEV-48125 675/225 mg or 900 mg vs placebo. Headache information was captured daily using an electronic headache diary. The primary endpoint was change from baseline ...
|Known for Chronic Migraine | Preventive Treatment | Monoclonal Antibody | 1 Week | Primary Endpoint|
Key People For Acute Treatment
Abouch Valenty Krymchantowski:Expert Impact
Concepts for whichAbouch Valenty Krymchantowskihas direct influence:Acute treatment, Cluster headache, Transformed migraine, Treatment migraine, Naproxen sodium, Monoclonal antibodies, Migraine treatment, Acute treatment migraine.
Abouch Valenty Krymchantowski:KOL impact
Concepts related to the work of other authors for whichfor which Abouch Valenty Krymchantowski has influence:Chronic migraine, Medication overuse, Acute treatment, Headache disorders, Naproxen sodium.
Is this your profile? Claim your profile Copy URL Embed Link to your profile